Research and Markets: PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022

Tue May 14, 2013 1:46pm EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/cn8qbb/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022" report to their offering.

GlobalData has released its new Country report, PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Spain from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting Spain Multiple Sclerosis market.

For more information visit http://www.researchandmarkets.com/research/cn8qbb/pharmapoint

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System